Functioning lung cell assay for modelling COVID-19 infections developed
A UK company has announced that their lung epithelium model can successfully be used to test potential treatments for COVID-19.
List view / Grid view
A UK company has announced that their lung epithelium model can successfully be used to test potential treatments for COVID-19.
The third phase of the ENCODE project has been released, with new information on genes and their potential regulators in their respective genomes.
Researchers have found that using GRL-0617, an PLpro inhibitor, in cell cultures blocked SARS-CoV-2 production and supported the cell immune response.
A study has identified more than 200 genes that drive the progression of glioblastoma and which the researchers say present drug targets.
Researchers say computational analyses suggest the bradykinin system may explain some of the symptoms of COVID-19, providing a drug target.
A study has shown that SRI-37330 is successful at improving the characteristics of diabetes in human pancreatic islets and animal models.
A study has demonstrated that the LY6E protein inhibits SARS-CoV-2 infection in human cell cultures, so a drug mimicking it could be a therapy for COVID-19.
After screening 12,000 existing drugs, scientists have identified 21 which prevent the replication of SARS-CoV-2 in concentrations safe for patients.
Researchers have revealed that the microRNA miR-218-5p promoted hair growth in mice, so is a promising drug target for hair loss.
A new technology named OligoFISSEQ has been created which can image and three-dimensionally map the genomes in hundreds of cells at the same time.
A team has shown that inhibiting the soluble epoxide hydrolase (sEH) enzyme in murine models can prevent the cognitive deterioration associated with Alzheimer's.
According to new research, sulfated polysaccharides extracted from seaweed were more effective at inhibiting SARS-CoV-2 infection in mammalian cells than remdesivir.
Researchers have created a new method of potentially treating herpes virus, by targeting the physical properties of the viral genome.
Researchers have modified the COVID-19 Spike protein for use in vaccines, which produces up to 10 times more protein than that of an earlier synthetic versions.
Researchers have developed MorphEUS, a technology to identify new drugs that combat M. tuberculosis by revealing how compounds destroy the bacteria.